Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
InternationalInternational
  • Country/Region
  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
  • Academy
  • Blog
Genomics Precision Diagnostic > Newborn Screening

Newborn Screening

Igenomix Newborn Screening is a genetic test that analyzes 237 genes linked to more than 200 conditions.

  • Technical Overview
  • Criteria & Clasification
  • Genes & Diseases
  • Documentation
  • Scientific evidence

Diseases with presentation in
infancy

Conditions with serious clinical
repercussions, affecting the
development of the newborn

POC Products of Conception

Potentially treatable
and actionable
alterations

Genetic disorders with
sufficient medical knowledge
and scientific evidence

Are you interested?

Request information
Or Email us at nacespain@igenomix.com
Genomics Precision Diagnostic > Newborn Screening

Newborn Screening

Igenomix Newborn Screening is a genetic test that analyzes 237 genes linked to more than 200 conditions.

  • Technical Overview
  • Criteria & Clasification
  • Genes & Diseases
  • Documentation
  • Scientific Evidence

Diseases with presentation in
infancy

Conditions with serious clinical
repercussions, affecting the
development of the newborn

POC Products of Conception

Potentially treatable
and actionable
alterations

Genetic disorders with
sufficient medical knowledge
and scientific evidence

Are you interested?

Request information
Or Email us at nacespain@igenomix.com
Overview
  • Newborn Screening
  • Benefits
  • Indications

Overview

  • Around 3%-4% of newborns are affected by a genetic condition.
  • Igenomix NBS identifies genetic disorders in newborn babies.
  • Newborn screening is a mandatory public health program that offers screening and follow-up medical care to all newborns for a variety of medical conditions.
  • Igenomix Newborn Screening Test is a comprehensive genetic test that analyzes 237 genes using Next Generation Sequencing (NGS) technologies allowing a direct approach of genetic disorders to reach a rapid, accurate diagnosis.
  • In addition, this test identifies a child is a healthy carrier of any of these genetic alterations.

NBS provides an extended panel of disorders analyzed with NGS based technologies offering a wider coverage than NBS done by the NHS.

  • These genes are responsible for developmental, genetic and metabolic disorders that cause serious health problems starting in early childhood.
  • The ultimate benefit is an early intervention to prevent intellectual and physical disabilities as well as life-threatening illnesses.
  • This test allows the detection of many more disorders than with a conventional heel prick test.
Know more

Goals of Conventional Newborn Screening (NBS)

The goals of newborn screening are:

  • Decrease morbidity and mortality of actionable diseases by performing an early intervention to improve neonatal and long-term health outcomes.
  • Provide a universal health service of screening to all newborns.
  • Identifying screen-positive newborns
  • Diagnosing conditions
  • Communication with families
  • Referral to treatment centers
  • Follow up with long-term outcomes
  • Educating physicians and patients.

What is the procedure?

Benefits of Using NGS/Clinical Utility

IGX uses Next Generation Sequencing (NGS) technologies to perform NBS vs tandem mass spectrometry (MS-MS).

Benefits of using NGS:

  • High clinical utility, by detecting +200 diseases.
  • Detect potentially treatable genetic conditions.
  • Allows an early clinical intervention of the baby.
  • Can avoid the development of symptoms, some of which may be irreversible..
  • Option for additional analysis and diagnosis at any stage of life.
  • The addition of DNA-based testing to primary NBS allows the diagnosis of conditions that could not be previously identified with a laboratory marker, given the nature of the technologies used.
  • Since NGS-WES technologies are used for the analysis, the patient’s data will be saved for the option for additional analysis and diagnostics at any stage of life.
  • Supports reproductive decisions and family planning.
  • Scientific advice for doctors and genetic counselling for patients, before and after the test.
  • Results: 25 calendar days.

 Indication

  • It is a screening test of genetic actionable diseases indicated for all newborns.
  • Early treatment is crucial to prevent complications and improve the
    prognosis for newborns.

Test Limitations

  • Newborn screening DOES NOT replace the potential value of carrier genetic testing (CGT) nor does carrier genetic testing replace newborn screening.
  • Performed during the first days of life.
  • Bucal swab.
Criteria & Clasification

What has been included and why?

The disease included in the Newborn Screening have been selected given the following criteria:

  • Diseases with presentation in infancy.
  • Conditions with serious clinical repercussions, affecting the development of the newborn.
  • Potentially treatable and actionable alterations.
  • Genetic disorders with sufficient medical knowledge and scientific evidence.

Igenomix Newborn Screening vs current NBS

NBS test incorporates all diseases from conventional newborn screening (heel prick test).

FAQs

Opening hours, contact details, lab address...

User manual

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix
Genes & Diseases
Gene List

The diseases included in the Igenomix NBS test can be classified in the following groups. You can find an example of a disease included in each group and its management.


Disease Group
Disorder
Signs and Symptoms
Patient Management
Result
MetabolicMaple Syrup Urine DiseaseCharacterized by poor feeding, lethargy, vomiting, a maple syrup odor in the cerumen and urine, encephalopathy and central respiratory failure if untreated.Dietary therapy to reduce toxic metabolites and achieve plasma concentrations of missing amino acids.Asymptomatic normal life
MetabolicMaple Syrup Urine DiseaseCharacterized by poor feeding, lethargy, vomiting, a maple syrup odor in the cerumen and urine, encephalopathy and central respiratory failure if untreated.Dietary therapy to reduce toxic metabolites and achieve plasma concentrations of missing amino acids.Asymptomatic normal life
ImmunodeficiencySevere Combined Immunodeficiency (SCID)Presentation due to recurrent, increasingly severe infections with opportunistic organisms and failure to thrive.Protective measures of prophylaxis with antibiotics, antifungals, antivirals and antibody replacementReduce the incidence of infections, slowing the progression and improve prognosis.
ImmunodeficiencySevere Combined Immunodeficiency (SCID)Presentation due to recurrent, increasingly severe infections with opportunistic organisms and failure to thrive.Protective measures of prophylaxis with antibiotics, antifungals, antivirals and antibody replacementReduce the incidence of infections, slowing the progression and improve prognosis.
NeurologyWilson DiseasePatients presents with abdominal pain, jaundice, hepatosplenomegaly, ascites, upper gastrointestinal bleed and mental status changes.Early initiation of copper chelationReduce accumulation of copper and prevent irreversible damage.
NeurologyWilson DiseasePatients presents with abdominal pain, jaundice, hepatosplenomegaly, ascites, upper gastrointestinal bleed and mental status changes.Early initiation of copper chelationReduce accumulation of copper and prevent irreversible damage.
PulmonologyCystic FibrosisNewborns present with rectal prolapse, meconium ileus, respiratory infections, pancreatic insufficiency, failure to thrive among other symptomsEarly initiation of pulmonary therapy, nutritional therapy, antibiotic prophylaxis, vaccination, bronchodilatorsDecrease the incidence of infections, maintain pulmonary function. Reduce progression and improve prognosis
PulmonologyCystic FibrosisNewborns present with rectal prolapse, meconium ileus, respiratory infections, pancreatic insufficiency, failure to thrive among other symptomsEarly initiation of pulmonary therapy, nutritional therapy, antibiotic prophylaxis, vaccination, bronchodilatorsDecrease the incidence of infections, maintain pulmonary function. Reduce progression and improve prognosis
EndocrinologyCongenital hypothyroidismMost infants are asymptomatic, those with symptoms typically present with lethargy, hoarse cry, feeding problems, constipation, myxoedema, macroglossia, among others.Early initiation of thyroid hormone replacement (oral levothyroxine)Prevent the development of impaired neurocognitive outcome, measured by intelligence quotient (IQ)
EndocrinologyCongenital hypothyroidismMost infants are asymptomatic, those with symptoms typically present with lethargy, hoarse cry, feeding problems, constipation, myxoedema, macroglossia, among others.Early initiation of thyroid hormone replacement (oral levothyroxine)Prevent the development of impaired neurocognitive outcome, measured by intelligence quotient (IQ)
ENTHereditary Hearing Loss*Infants will most likely remain asymptomatic until early childhood where the patient will have trouble understanding words, hearing consonants, avoidance of social setting etcEarly initiation of hearing aids, speech therapy and language therapyPrevent developmental and speech delay
ENTHereditary Hearing Loss*Infants will most likely remain asymptomatic until early childhood where the patient will have trouble understanding words, hearing consonants, avoidance of social setting etcEarly initiation of hearing aids, speech therapy and language therapyPrevent developmental and speech delay
HemoglobinopathiesSickle cell anemiaNewborns can present with severe anemia, vaso-occlusive crisis, chronic abdominal pain, hyposplenism and infections.Early initiation of primary prevention of acute complications, as well as hematopoietic stem cell transplantationPrevent recurrent acute vaso-occlusive episodes and with successful hematopoietic stem cell transplantation achieve a normal asymptomatic life
HemoglobinopathiesSickle cell anemiaNewborns can present with severe anemia, vaso-occlusive crisis, chronic abdominal pain, hyposplenism and infections.Early initiation of primary prevention of acute complications, as well as hematopoietic stem cell transplantationPrevent recurrent acute vaso-occlusive episodes and with successful hematopoietic stem cell transplantation achieve a normal asymptomatic life
NeuromuscularSpinal Muscular AtrophyCharacterized by diffuse symmetric proximal muscle weakness greater in lower than upper extremities with absent or markedly decreased deep tendon reflexes.Early initiation of disease-modifying therapy and supportive therapyImprove quality of life and increase survival of affected individuals
NeuromuscularSpinal Muscular AtrophyCharacterized by diffuse symmetric proximal muscle weakness greater in lower than upper extremities with absent or markedly decreased deep tendon reflexes.Early initiation of disease-modifying therapy and supportive therapyImprove quality of life and increase survival of affected individuals
Documentation

Clinical Sheet

Download

Brochure

Download

Gene List

Download

Report Guidelines

Download
Scientific evidence

Relevant related studies:

ACOG Committee Opinion No. 778 Summary: Newborn Screening and the Role of the Obstetrician–Gynecologist. (2019). Obstetrics & Gynecology, 133(5), 1073-1074. doi: 10.1097/aog.0000000000003246

https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html#:~:text=The%20RUSP%20is%20a%20list,newborn%20screening%20(NBS)%20programs

van Campen, Sollars, Thomas, Bartlett, Milano, & Parker et al. (2019). Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service. International Journal Of Neonatal Screening, 5(4), 40. doi: 10.3390/ijns5040040

Adhikari, A. N., Gallagher, R. C., Wang, Y., Currier, R. J., Amatuni, G., Bassaganyas, L., Chen, F., Kundu, K., Kvale, M., Mooney, S. D., Nussbaum, R. L., Randi, S. S., Sanford, J., Shieh, J. T., Srinivasan, R., Sunderam, U., Tang, H., Vaka, D., Zou, Y., Koenig, B. A., … Brenner, S. E. (2020). The role of exome sequencing in newborn screening for inborn errors of metabolism. Nature medicine, 26(9), 1392–1397. https://doi.org/10.1038/s41591-020-0966-5

Rajabi, F. (2018). Updates in Newborn Screening. Pediatric Annals, 47(5). doi: 10.3928/19382359-20180426-01

Wang, W., Yang, J., Xue, J., Mu, W., Zhang, X., Wu, W., Xu, M., Gong, Y., Liu, Y., Zhang, Y., Xie, X., Gu, W., Bai, J., & Cram, D. S. (2019). A comprehensive multiplex PCR based exome-sequencing assay for rapid bloodspot confirmation of inborn errors of metabolism. BMC medical genetics, 20(1), 3. https://doi.org/10.1186/s12881-018-0731-5

Waisbren, S., Bäck, D., Liu, C., Kalia, S., Ringer, S., Holm, I., & Green, R. (2014). Parents are interested in newborn genomic testing during the early postpartum period. Genetics In Medicine, 17(6), 501-504. doi: 10.1038/gim.2014.139 

Pereira, S., Robinson, J. O., Gutierrez, A. M., Petersen, D. K., Hsu, R. L., Lee, C. H., Schwartz, T. S., Holm, I. A., Beggs, A. H., Green, R. C., McGuire, A. L., & BabySeq Project Group (2019). Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project. Pediatrics, 143(Suppl 1), S6–S13. https://doi.org/10.1542/peds.2018-1099C

 

Overview
  • Newborn Screening
  • Benefits
  • Indications

Overview

  • Around 3%-4% of newborns are affected by a genetic condition.
  • Igenomix NBS identifies genetic disorders in newborn babies.
  • Newborn screening is a mandatory public health program that offers screening and follow-up medical care to all newborns for a variety of medical conditions.
  • Igenomix Newborn Screening Test is a comprehensive genetic test that analyzes 237 genes using Next Generation Sequencing (NGS) technologies allowing a direct approach of genetic disorders to reach a rapid, accurate diagnosis.
  • In addition, this test identifies a child is a healthy carrier of any of these genetic alterations.

NBS provides an extended panel of disorders analyzed with NGS based technologies offering a wider coverage than NBS done by the NHS.

  • These genes are responsible for developmental, genetic and metabolic disorders that cause serious health problems starting in early childhood.
  • The ultimate benefit is an early intervention to prevent intellectual and physical disabilities as well as life-threatening illnesses.
  • This test allows the detection of many more disorders than with a conventional heel prick test.
Know more

Goals of Conventional Newborn Screening (NBS)

The goals of newborn screening are:

  • Decrease morbidity and mortality of actionable diseases by performing an early intervention to improve neonatal and long-term health outcomes.
  • Provide a universal health service of screening to all newborns.
  • Identifying screen-positive newborns
  • Diagnosing conditions
  • Communication with families
  • Referral to treatment centers
  • Follow up with long-term outcomes
  • Educating physicians and patients.
What is the procedure?

Benefits of Using NGS/Clinical Utility

IGX uses Next Generation Sequencing (NGS) technologies to perform NBS vs tandem mass spectrometry (MS-MS).

Benefits of using NGS:

  • High clinical utility, by detecting +200 diseases.
  • Detect potentially treatable genetic conditions.
  • Allows an early clinical intervention of the baby.
  • Can avoid the development of symptoms, some of which may be irreversible..
  • Option for additional analysis and diagnosis at any stage of life.
  • The addition of DNA-based testing to primary NBS allows the diagnosis of conditions that could not be previously identified with a laboratory marker, given the nature of the technologies used.
  • Since NGS-WES technologies are used for the analysis, the patient’s data will be saved for the option for additional analysis and diagnostics at any stage of life.
  • Supports reproductive decisions and family planning.
  • Scientific advice for doctors and genetic counselling for patients, before and after the test.
  • Results: 25 calendar days.

 Indication

  • It is a screening test of genetic actionable diseases indicated for all newborns.
  • Early treatment is crucial to prevent complications and improve the
    prognosis for newborns.

Test Limitations

  • Newborn screening DOES NOT replace the potential value of carrier genetic testing (CGT) nor does carrier genetic testing replace newborn screening.
  • Performed during the first days of life.
  • Bucal swab.
Criteria & Clasification

What has been included and why?

The disease included in the Newborn Screening have been selected given the following criteria:

  • Diseases with presentation in infancy.
  • Conditions with serious clinical repercussions, affecting the development of the newborn.
  • Potentially treatable and actionable alterations.
  • Genetic disorders with sufficient medical knowledge and scientific evidence.

Igenomix Newborn Screening vs current NBS

NBS test incorporates all diseases from conventional newborn screening (heel prick test).

Genes & Diseases
Gene List

Disease Group
Disorder
Signs and Symptoms
Patient Management
Result
MetabolicMaple Syrup Urine DiseaseCharacterized by poor feeding, lethargy, vomiting, a maple syrup odor in the cerumen and urine, encephalopathy and central respiratory failure if untreated.Dietary therapy to reduce toxic metabolites and achieve plasma concentrations of missing amino acids.Asymptomatic normal life
MetabolicMaple Syrup Urine DiseaseCharacterized by poor feeding, lethargy, vomiting, a maple syrup odor in the cerumen and urine, encephalopathy and central respiratory failure if untreated.Dietary therapy to reduce toxic metabolites and achieve plasma concentrations of missing amino acids.Asymptomatic normal life
ImmunodeficiencySevere Combined Immunodeficiency (SCID)Presentation due to recurrent, increasingly severe infections with opportunistic organisms and failure to thrive.Protective measures of prophylaxis with antibiotics, antifungals, antivirals and antibody replacementReduce the incidence of infections, slowing the progression and improve prognosis.
ImmunodeficiencySevere Combined Immunodeficiency (SCID)Presentation due to recurrent, increasingly severe infections with opportunistic organisms and failure to thrive.Protective measures of prophylaxis with antibiotics, antifungals, antivirals and antibody replacementReduce the incidence of infections, slowing the progression and improve prognosis.
NeurologyWilson DiseasePatients presents with abdominal pain, jaundice, hepatosplenomegaly, ascites, upper gastrointestinal bleed and mental status changes.Early initiation of copper chelationReduce accumulation of copper and prevent irreversible damage.
NeurologyWilson DiseasePatients presents with abdominal pain, jaundice, hepatosplenomegaly, ascites, upper gastrointestinal bleed and mental status changes.Early initiation of copper chelationReduce accumulation of copper and prevent irreversible damage.
PulmonologyCystic FibrosisNewborns present with rectal prolapse, meconium ileus, respiratory infections, pancreatic insufficiency, failure to thrive among other symptomsEarly initiation of pulmonary therapy, nutritional therapy, antibiotic prophylaxis, vaccination, bronchodilatorsDecrease the incidence of infections, maintain pulmonary function. Reduce progression and improve prognosis
PulmonologyCystic FibrosisNewborns present with rectal prolapse, meconium ileus, respiratory infections, pancreatic insufficiency, failure to thrive among other symptomsEarly initiation of pulmonary therapy, nutritional therapy, antibiotic prophylaxis, vaccination, bronchodilatorsDecrease the incidence of infections, maintain pulmonary function. Reduce progression and improve prognosis
EndocrinologyCongenital hypothyroidismMost infants are asymptomatic, those with symptoms typically present with lethargy, hoarse cry, feeding problems, constipation, myxoedema, macroglossia, among others.Early initiation of thyroid hormone replacement (oral levothyroxine)Prevent the development of impaired neurocognitive outcome, measured by intelligence quotient (IQ)
EndocrinologyCongenital hypothyroidismMost infants are asymptomatic, those with symptoms typically present with lethargy, hoarse cry, feeding problems, constipation, myxoedema, macroglossia, among others.Early initiation of thyroid hormone replacement (oral levothyroxine)Prevent the development of impaired neurocognitive outcome, measured by intelligence quotient (IQ)
ENTHereditary Hearing Loss*Infants will most likely remain asymptomatic until early childhood where the patient will have trouble understanding words, hearing consonants, avoidance of social setting etcEarly initiation of hearing aids, speech therapy and language therapyPrevent developmental and speech delay
ENTHereditary Hearing Loss*Infants will most likely remain asymptomatic until early childhood where the patient will have trouble understanding words, hearing consonants, avoidance of social setting etcEarly initiation of hearing aids, speech therapy and language therapyPrevent developmental and speech delay
HemoglobinopathiesSickle cell anemiaNewborns can present with severe anemia, vaso-occlusive crisis, chronic abdominal pain, hyposplenism and infections.Early initiation of primary prevention of acute complications, as well as hematopoietic stem cell transplantationPrevent recurrent acute vaso-occlusive episodes and with successful hematopoietic stem cell transplantation achieve a normal asymptomatic life
HemoglobinopathiesSickle cell anemiaNewborns can present with severe anemia, vaso-occlusive crisis, chronic abdominal pain, hyposplenism and infections.Early initiation of primary prevention of acute complications, as well as hematopoietic stem cell transplantationPrevent recurrent acute vaso-occlusive episodes and with successful hematopoietic stem cell transplantation achieve a normal asymptomatic life
NeuromuscularSpinal Muscular AtrophyCharacterized by diffuse symmetric proximal muscle weakness greater in lower than upper extremities with absent or markedly decreased deep tendon reflexes.Early initiation of disease-modifying therapy and supportive therapyImprove quality of life and increase survival of affected individuals
NeuromuscularSpinal Muscular AtrophyCharacterized by diffuse symmetric proximal muscle weakness greater in lower than upper extremities with absent or markedly decreased deep tendon reflexes.Early initiation of disease-modifying therapy and supportive therapyImprove quality of life and increase survival of affected individuals
Documentation

Clinical Sheet

Download

Brochure

Download

Gene List

Download

Report Guidelines

Download
Scientific Evidence

Relevant related studies:

ACOG Committee Opinion No. 778 Summary: Newborn Screening and the Role of the Obstetrician–Gynecologist. (2019). Obstetrics & Gynecology, 133(5), 1073-1074. doi: 10.1097/aog.0000000000003246

https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html#:~:text=The%20RUSP%20is%20a%20list,newborn%20screening%20(NBS)%20programs

van Campen, Sollars, Thomas, Bartlett, Milano, & Parker et al. (2019). Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service. International Journal Of Neonatal Screening, 5(4), 40. doi: 10.3390/ijns5040040

Adhikari, A. N., Gallagher, R. C., Wang, Y., Currier, R. J., Amatuni, G., Bassaganyas, L., Chen, F., Kundu, K., Kvale, M., Mooney, S. D., Nussbaum, R. L., Randi, S. S., Sanford, J., Shieh, J. T., Srinivasan, R., Sunderam, U., Tang, H., Vaka, D., Zou, Y., Koenig, B. A., … Brenner, S. E. (2020). The role of exome sequencing in newborn screening for inborn errors of metabolism. Nature medicine, 26(9), 1392–1397. https://doi.org/10.1038/s41591-020-0966-5

Rajabi, F. (2018). Updates in Newborn Screening. Pediatric Annals, 47(5). doi: 10.3928/19382359-20180426-01

Wang, W., Yang, J., Xue, J., Mu, W., Zhang, X., Wu, W., Xu, M., Gong, Y., Liu, Y., Zhang, Y., Xie, X., Gu, W., Bai, J., & Cram, D. S. (2019). A comprehensive multiplex PCR based exome-sequencing assay for rapid bloodspot confirmation of inborn errors of metabolism. BMC medical genetics, 20(1), 3. https://doi.org/10.1186/s12881-018-0731-5

Waisbren, S., Bäck, D., Liu, C., Kalia, S., Ringer, S., Holm, I., & Green, R. (2014). Parents are interested in newborn genomic testing during the early postpartum period. Genetics In Medicine, 17(6), 501-504. doi: 10.1038/gim.2014.139 

Pereira, S., Robinson, J. O., Gutierrez, A. M., Petersen, D. K., Hsu, R. L., Lee, C. H., Schwartz, T. S., Holm, I. A., Beggs, A. H., Green, R. C., McGuire, A. L., & BabySeq Project Group (2019). Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project. Pediatrics, 143(Suppl 1), S6–S13. https://doi.org/10.1542/peds.2018-1099C

 

FAQs

Opening hours, contact details, lab address...

User manual

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Other services

WES

Analyze the entire coding sequence of a gene

More information
CGT Carrier Genetic Test

CGT

Determines the risk of having a child with a genetic disease

More information

CMA

Deletions or duplications at the chromosomal level

More information

Other services

WES

Analyze the entire coding sequence of a gene

More information
CGT Carrier Genetic Test

CGT

Determines the risk of having a child with a genetic disease

More information

CMA

Deletions or duplications at the chromosomal level

More information

Igenomix is in the media

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Argentina
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
Country/Region

[2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press   

Request Information


  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information